TRANSLAD - Translational medicine in development disorders
  • LabKey Access
  • French
  • English

TRANSLAD - Translational medicine in development disorders

TRANSLAD

A best-practice project focussing specifically on the development of healthcare, research and education in the area of rare developmental disorder diseases.

The principal axes of FHU-TRANSLAD
  • Treat Treat

    A centre for patient evaluation and multidisciplinary care

  • Innovate Innovate

    A diagnostic centre at the cutting edge of molecular genetic technology.

  • Teach and Train Teach and Train

    A training and genomics information referral centre for hereditary diseases

  • Humanise Humanise

    A think-tank on societal and ethical issues

  • Find Find

    A clinical, molecular, neuro-cognitive and pathophysiological research centre

  • Home
  • Introduction
  • Diseases involved
  • Principal Axes
    • Area 1 : Treat
    • Area 2 : Innovate
    • Area 3 : Teach and Train
    • Area 4 : Humanise
    • Area 5 : Find
  • Follow-up
  • Coordination
  • Teams
    • Presentation
    • Diagnostics and healthcare teams included in FHU
    • Research teams included in FHU
    • Teams partnering with FHU-TRANSLAD
  • Support us
  • Home
  • Home
  • Principal Axes
  • Innovate
  • The Dijon Bourgogne University Hospital Functional Unit for innovation in rare disease diagnostics
  • Intellectual Disability and Developmental Disorders: Molecular Diagnosis by High-Throughput Exome Sequencing

Intellectual Disability and Developmental Disorders: Molecular Diagnosis by High-Throughput Exome Sequencing

The ES performed in our laboratory is part of a generic treatment path involving biological analysis for patients with a rare genetic disease (cf. Figure). Requests for this come from Dijon University Hospital as well as from all over France via Orphanomix.

Parcours générique du SHD-E

The genome-wide HTS test is a dynamic one which we have demonstrated to be of major clinical relevance for potential repeat data analyses vis-à-vis rare diseases. A repeat analysis procedure is arranged solely at the request of the clinician who has seen the patient.
With the current arrangement, UF6254 can perform one ES test per 500 patients per year for all of the genetic centres in France. In 2017, an ES result was obtained for 351 patients, with a positive molecular diagnosis for 101 patients (29%) (cf. table).

Area 2 : Innovate

  • Introduction
  • The Dijon Bourgogne University Hospital high-throughput sequencing platform
    • High-throughput sequencing
  • The bioinformatics platform for data analysis
  • The Dijon Bourgogne University Hospital Functional Unit for innovation in rare disease diagnostics
    • Intellectual Disability and Developmental Disorders
    • Mosaic-activating developmental disorders with cutaneous expression
  • The Orphanomix Spin-Off

 

Other axes

  • Area 1 : Treat
  • Area 2 : Innovate
  • Area 3 : Teach and Train
  • Area 4 : Humanise
  • Area 5 : Find

CHU Dijon - 14 rue Paul Gaffarel - BP 77908 - 21079 Dijon - France
Tél. : 03 80 29 53 13 - Fax : 03 80 29 32 66 - E-mail